Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451031 | 0.93 | ALDH1A1 (0.42) | TSHRGAAALOX15PTGDR2NPC1 | |
| SCHEMBL5459679 | 0.93 | KMT2A (0.37) | GAAPTGDR2SMN1; SMN2NPC1KMT2A | |
| SCHEMBL5458929 | 0.89 | ALDH1A1 (0.39) | PTGDR2NPC1KMT2AALDH1A1HPGD | |
| SCHEMBL5452215 | 0.87 | LMNA (0.39) | PTGDR2NPC1KMT2AALDH1A1HPGD | |
| SCHEMBL5445292 | 0.86 | TSHR (0.45) | TSHRGAAALOX15PTGDR2SMN1; SMN2 | |
| SCHEMBL5459211 | 0.80 | ALDH1A1 (0.52) | TSHRGAAALOX15PTGDR2NPC1 | |
| SCHEMBL5454884 | 0.80 | ALDH1A1 (0.45) | TSHRGAAALOX15SMN1; SMN2NPC1 | |
| SCHEMBL5458935 | 0.79 | GAA (0.43) | TSHRGAAALOX15PTGDR2SMN1; SMN2 | |
| SCHEMBL5452471 | 0.77 | MAPT (0.40) | TSHRGAAALOX15SMN1; SMN2NPC1 | |
| SCHEMBL5456768 | 0.77 | KMT2A (0.45) | GAAPTGDR2SMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | TSHR 1155/4885GAA 639/4885ALOX15 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.